Global Alliance for TB Drug Development

Global Alliance for TB Drug Development
Name	Global Alliance for TB Drug Development
Type	Non-profit public-private partnership
Founded	2000
Headquarters	New York City
Focus	Tuberculosis drug development, clinical trials, access to medicines

Contents

Global Alliance for TB Drug Development is a non-profit public–private partnership founded to accelerate development of new therapeutics for Tuberculosis in response to rising cases of Multidrug-resistant tuberculosis and HIV/AIDS-associated co-infection. The Alliance worked with pharmaceutical companies such as GlaxoSmithKline, Johnson & Johnson, and Bayer as well as research institutions including Centers for Disease Control and Prevention, National Institutes of Health, and London School of Hygiene & Tropical Medicine to coordinate clinical development, regulatory strategy, and access planning. Its programs interfaced with global health actors like the World Health Organization, United Nations, and Bill & Melinda Gates Foundation to align priorities for treatment pipelines, clinical trials, and implementation research.

History

The Alliance was established in 2000 following discussions involving Stop TB Partnership, World Health Organization, and philanthropists linked to the Clinton Foundation and Wellcome Trust after recognition of escalating resistance documented by WHO Global TB Report and surveillance networks in South Africa, India, and Russia. Early milestones included collaboration on preclinical screening with National Institute of Allergy and Infectious Diseases and delivery of candidate molecules through partnerships with Pfizer, Eli Lilly and Company, and academic groups at University of California, San Francisco and Columbia University. During the 2000s the Alliance coordinated Phase II and Phase III trials across sites in Peru, China, South Africa, and Vietnam, adapting trial designs endorsed by European Medicines Agency and Food and Drug Administration. By the 2010s it had supported late-stage development for regimens involving new chemical entities and repurposed drugs in tandem with policy dialogue at Global Fund to Fight AIDS, Tuberculosis and Malaria and implementation partners such as Médecins Sans Frontières.

The Alliance aimed to shorten time-to-market for novel therapies by bridging discovery science at institutions like Imperial College London and Max Planck Society with commercialization partners such as Novartis and Roche. Objectives included advancing candidates through preclinical pipelines managed with input from European Commission research frameworks and coordinating multicenter clinical trials overseen by ethics committees tied to Harvard Medical School and Johns Hopkins University. It prioritized regimens effective against multidrug-resistant tuberculosis and compatible with antiretroviral regimens used for HIV/AIDS treatment programs such as those administered by PEPFAR and national programs in Brazil, China, and South Africa.

The Alliance organized R&D into discovery, translational, and clinical portfolios, partnering with chemical libraries from GlaxoSmithKline, high-throughput screening facilities at Broad Institute, and pharmacology groups at Scripps Research. Clinical programmes included adaptive trial designs informed by statisticians from London School of Hygiene & Tropical Medicine and regulatory consultation with European Medicines Agency and Food and Drug Administration. The Alliance supported studies of novel classes alongside repurposed agents like linezolid and bedaquiline developed with companies such as Janssen Pharmaceuticals and Johnson & Johnson, and coordinated access strategies linked to procurement mechanisms used by UNICEF and Global Drug Facility.

Funding and partnerships combined philanthropic grants from the Bill & Melinda Gates Foundation and Rockefeller Foundation with investments from corporate partners including GlaxoSmithKline and collaborations with academic consortia at University of Oxford and University of Cape Town. The Alliance engaged multilateral funders such as Global Fund to Fight AIDS, Tuberculosis and Malaria and policy agencies like United States Agency for International Development to support trial networks in Peru, Vietnam, and Philippines. It coordinated intellectual property arrangements with entities such as Medicines Patent Pool and negotiated manufacturing partnerships with generic producers in India and South Korea to enable scale-up and country-level introduction under procurement frameworks used by WHO Prequalification.

Outcomes attributed to the Alliance include advancement of multiple candidates into late-stage trials, contributions to guidance published by World Health Organization on shorter regimens, and facilitation of regulatory submissions to European Medicines Agency and Food and Drug Administration. Its work influenced programmatic adoption in national TB programmes in South Africa, India, and Philippines, and supported implementation projects run by Médecins Sans Frontières and Partners In Health. The Alliance’s collaborations helped catalyse private sector engagement from companies such as Novartis and Pfizer and informed financing strategies by Global Fund to Fight AIDS, Tuberculosis and Malaria and donor policies at United Kingdom Department for International Development.

Governance combined a board with representatives from academic institutions like Columbia University and University of Oxford, donor organizations including the Bill & Melinda Gates Foundation and Wellcome Trust, and industry partners such as GlaxoSmithKline and Johnson & Johnson. Operational management worked with clinical advisory groups featuring experts from Harvard Medical School, London School of Hygiene & Tropical Medicine, and National Institutes of Health, and compliance functions aligned with regulatory bodies such as European Medicines Agency and Food and Drug Administration. The Alliance structured project teams to liaise with country ministries of health in South Africa, India, and Peru and with procurement agencies including Global Drug Facility to ensure translation from trials to policy.